Ruxolitinib cream for stubborn skin in dermatomyositis
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial tests a cream called ruxolitinib for people with dermatomyositis whose skin symptoms haven't improved with standard treatments. It aims to see if this cream can reduce rash and activity when added to your current medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have dermatomyositis with skin symptoms that haven't improved after trying steroids and at least one other systemic medication
- Your skin rash covers at least 1% but less than 20% of your body and is moderately active
- You have tried at least one topical cream (like steroid or tacrolimus) in the past but it didn't work
- You have been on the same systemic medications for at least 2 months and agree to keep them stable during the study
- You are willing to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
This trial tests a cream called ruxolitinib to see if it can safely and effectively restore skin color in children with vitiligo. It may help reduce white patches on the skin.
This study tests a cream called ruxolitinib for people with hidradenitis suppurativa (HS). The goal is to see how much of the cream is absorbed when it's applied to a large area of the body.
This trial tests a cream (ruxolitinib) on discoid lupus skin lesions. It aims to see if the cream can reduce DLE symptoms in adults.
This study tests a cream called ruxolitinib on the skin rash caused by graft-versus-host disease (GVHD) after a bone marrow or stem cell transplant. The goal is to see if the cream safely reduces the rash without needing stronger medicines by mouth.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.